Skip to content

Study on the effective dose of 0.25% ropivacaine for brachial plexus nerve block in children with supracondylar humerus fracture

An effective dose study of 0.25% ropivacaine for brachial plexus block with different approaches in pediatric supracondylar humeral fracture surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097010
Enrollment
Unknown
Registered
2025-02-11
Start date
2024-06-11
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supracondylar fracture of humerus

Interventions

Group A(1~3 years old):Supraclavicular brachial plexus block, if the nerve block fails, the next patients ropivacaine dose is increased by 10% of the initial dose or otherwise decreased by 10%. For pa
Group B(4~6 years old):Supraclavicular brachial plexus block, if the nerve block fails, the next patients ropivacaine dose is increased by 10% of the initial dose or otherwise decreased by 10%. For pa
Group C(7~10 years old):Supraclavicular brachial plexus block, if the nerve block fails, the next patients ropivacaine dose is increased by 10% of the initial dose or otherwise decreased by 10%. For p

Sponsors

Fuzhou Second General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 10 Years

Inclusion criteria

Inclusion criteria: (1) Children aged 1~10 years, ASA grade I ~ II, undergoing elective surgery for supracondylar fractures of humerus; (2) Without previous history of perielbow surgery; (3) Without neurological impairment; (4) The informed consent of the parents or legal guardians has been obtained.

Exclusion criteria

Exclusion criteria: (1) Multiple injuries or open fractures; (2) Known allergy history of ropivacaine; (3) Without clear and complete medical records; (4) Delayed onset of elbow fracture; (5) Neurological or neuromuscular disease or any other systemic disease; (6) Without the informed consent of parents or legal guardians; (7) Other factors affecting the research results.

Design outcomes

Primary

MeasureTime frame
Heart rate ;Body movement in operation;Mean arterial pressure;

Secondary

MeasureTime frame
FLACC pain scale score;Wong-Baker faces scale revision (FPS-R);Numerical rating scale (NRS);The occurrence of perioperative complications;Analgesic remedies;Duration of anesthesia;Operation time;Recovery time;Length of stay;

Countries

China

Contacts

Public ContactWang Bingyan

Fuzhou Second General Hospital

bingyanwang5@163.com+86 159 8023 4348

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026